Previous 10 | Next 10 |
2023-09-29 04:41:48 ET ModeX Therapeutics, an OPKO Health ( NASDAQ: OPK ) company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, to advance a platform and specific candidates designed to address a range of public health threats in vir...
NATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at th...
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will su...
2023-09-09 03:17:14 ET Summary Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable in recent quarters, unlike Pfizer, whose demand f...
2023-08-04 01:00:22 ET Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q2 2023 Earnings Call Aug 03, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Opko Health (OPK) Q2 2023 Earnings Call Transcript
2023-08-04 00:17:04 ET OPKO Health, Inc. (OPK) Q2 2023 Earnings Conference Call August 3, 2023 16:30 ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & Chief Executive Officer Elias Zerhouni - President & Vice Chairm...
2023-08-03 16:10:44 ET OPKO Health press release ( NASDAQ: OPK ): Q2 GAAP EPS of -$0.03 beats by $0.04 . Revenue of $265.4M (-14.4% Y/Y) beats by $63.43M . For further details see: OPKO Health GAAP EPS of -$0.03 beats by $0.04, revenue of $265.4M beats by...
MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA approved NGENLA™ for pediatric ...
2023-07-31 14:19:19 ET Summary OPKO Health stock has bounced back since February but remains down over 11% since last year. OPK stock's rally in recent months has been supported by strong buying volume and positive earnings revisions. The company's collaboration with Merck and...
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. OPKO’s senior management will provide a b...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...